跳至主要内容
临床试验/JPRN-UMIN000042717
JPRN-UMIN000042717已完成未知

Circulating microparticles as biomarkers in COVID-19 associated coagulopathy: a prospective cohort study - The role of microparticles in coagulopathy of COVID-19: a prospective cohort study

Tohoku university0 个研究点目标入组 99 人开始时间: 2020年12月10日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
99

研究概览

简要总结

o difference was found in the EV levels between the non-coagulopathy and coagulopathy groups.We conducted three group comparison, COVID-19 coagulopathy group, non-coagulopathy group, and healthy volunteer. In the Kruskal Wallis test, the CD41 positive EV levels were statistically different among the groups. The coagulopathy group had higher CD41 positive EV levels than the healthy volunteer group.

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 120years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) patients in which informed consent could not be obtained from the person or close relatives (2) patients who have other infectious diseases (3) patients with end-stage heart failure( defined as NYHA class4) (4) patients with end-stage liver failure (defined as Child-Pugh classification C) (5) patients with progressive cancer, or patients undergoing cancer treatment (6) patients who are pregnant (7) patients who have participated in this study (8) patients who are diagnosed as COVID-19 accidentally and need emergency treatment for other diseases

研究者

相似试验